

October 23, 2025

<p>To</p> <p>The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p>Code: 540222</p>	<p>To</p> <p>The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p>Code: LAURUSLABS</p>
--	--

Dear Sir / Madam,

Sub: Outcome of the Board Meeting – October 23, 2025

The Board of Directors of the Company at their meeting held on October 23, 2025 have resolved as follows:

(1) Approval of Unaudited Financial Results for the quarter and half-year ended September 30, 2025:

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), the Board of Directors approved the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and half-year ended September 30, 2025 at their meeting held on October 23, 2025, which are **annexed** herewith along with the Limited Review Reports issued by Deloitte Haskins & Sells LLP, the Statutory Auditors of the Company.

The financial results are also available on the website of the Company at www.lauruslabs.com and also on the websites of BSE Limited and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseindia.com respectively.

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District – 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad – 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

(2) Approval for the payment of Interim Dividend for FY 2025-26:

The Board of Directors approved the payment of Interim Dividend of Rs.0.80/- (40%) per equity share of Rs.2/- each, for the Financial Year 2025-26.

Further, pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, the Company has fixed “October 31, 2025” as the “Record Date” for determining the eligibility of the Shareholders. The Dividend amount will be paid on or after November 12, 2025.

The Board Meeting commenced at 02.00 p.m. and concluded at 02.55 p.m.

This is for your information and records.

Thanking you,

Yours sincerely,

For **Laurus Labs Limited**

G. Venkateswar Reddy

Company Secretary & Compliance Officer

Encl: A/a

Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anaparthi District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

LAURUS LABS LIMITED
(CIN: L24239AP2005PLC047518)

Regd. Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021

Corp. Office: 2nd Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India.

Tel: +91 040 3980 4333 ; Fax : +91 040 3980 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

STATEMENT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

₹ in Crores

Sl. No.	Particulars	Quarter ended			Six months ended		Year ended
		30-Sep-25	30-Jun-25	30-Sep-24	30-Sep-25	30-Sep-24	31-Mar-25
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	(a) Revenue from operations	1,653.47	1,569.57	1,223.70	3,223.04	2,418.61	5,553.96
	(b) Other income	26.96	10.43	4.60	37.39	7.11	75.10
	Total income	1,680.43	1,580.00	1,228.30	3,260.43	2,425.72	5,629.06
2	Expenses						
	(a) Cost of materials consumed	676.75	599.41	577.17	1,276.16	1,149.22	2,428.55
	(b) Purchase of traded goods	30.70	38.50	25.59	69.20	48.26	105.36
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(44.01)	(0.56)	(54.46)	(44.57)	(112.33)	(55.93)
	(d) Employee benefits expense	215.56	214.80	178.72	430.36	352.70	719.52
	(e) Other expenses	371.21	335.29	318.35	706.50	631.23	1,301.18
	(f) Depreciation and amortisation expense	120.49	116.84	107.51	237.33	213.57	430.09
	(g) Finance costs	40.00	51.50	52.61	91.50	101.80	216.00
	Total expenses	1,410.70	1,355.78	1,205.49	2,766.48	2,384.45	5,144.77
3	Profit before tax (1-2)	269.73	224.22	22.81	493.95	41.27	484.29
4	Tax expense						
	(a) Current tax	87.91	60.02	23.18	147.93	41.59	156.90
	(b) Deferred tax	(11.93)	3.12	(18.09)	(8.81)	(30.25)	(27.02)
	Total Tax expense	75.98	63.14	5.09	139.12	11.34	129.88
5	Net Profit after tax (3-4)	193.75	161.08	17.72	354.83	29.93	354.41
6	Share of profit from associates and joint venture, net of tax	0.74	0.60	2.23	1.34	2.70	3.93
7	Net Profit after taxes and share of profit from associates and joint venture(5+6)	194.49	161.68	19.95	356.17	32.63	358.34
8	Other comprehensive income						
(a)	Items that will not be reclassified subsequently to profit or loss:						
	(i) Remeasurement gains/(losses) on defined benefit plans	(0.26)	(0.25)	0.38	(0.51)	0.76	(1.87)
	(ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	0.07	0.06	(0.09)	0.13	(0.19)	0.50
	(iii) Share in Other comprehensive income of associates and joint venture, net of tax	(0.01)	-	-	(0.01)	-	(0.01)
(b)	Items that will be reclassified subsequently to profit or loss:						
	Exchange differences on translating the financial statements of foreign operations	(5.47)	(0.52)	(0.71)	(5.99)	(0.68)	(2.27)
	Total other comprehensive income/(loss), net of tax	(5.67)	(0.71)	(0.42)	(6.38)	(0.11)	(3.65)
9	Total comprehensive income (7+8)	188.82	160.97	19.53	349.79	32.52	354.69
10	Profit for the period attributable to:						
	i) Equity holders of the company	194.97	163.02	19.84	357.99	32.35	358.32
	ii) Non-controlling interests	(0.48)	(1.34)	0.11	(1.82)	0.28	0.02
11	Total comprehensive income for the period attributable to:						
	i) Equity holders of the company	189.30	162.31	19.42	351.61	32.24	354.67
	ii) Non-controlling interests	(0.48)	(1.34)	0.11	(1.82)	0.28	0.02
12	Paid-up equity share capital (face value ₹ 2/- each)	107.96	107.96	107.83	107.96	107.83	107.85
13	Other equity						4,364.71
14	Earnings per equity share (face value ₹ 2/- each)						
	- Basic (₹)	3.61	3.02	0.37	6.63	0.60	6.65
	- Diluted (₹)	3.61	3.02	0.37	6.63	0.60	6.64
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

See accompanying notes to the financial results



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, E info@lauruslabs.com

F +91 891 682 1103, W lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,

F +91 40 6659 4320 / 3980 4320

Consolidated Balance Sheet

₹ in Crores

Sl. No.	Particulars	As at September 30, 2025	As at March 31, 2025
		Unaudited	Audited
I	ASSETS		
	Non-current assets		
(a)	Property, plant and equipment	3,800.23	3,668.46
(b)	Right-of-use assets	177.70	189.14
(c)	Capital work-in- progress	540.81	458.36
(d)	Goodwill	246.30	246.30
(e)	Other intangible assets	17.73	19.32
(f)	Financial assets		
	(i) Investments	261.32	233.26
	(ii) Other financial assets	46.42	48.66
(g)	Income tax assets (net)	7.25	6.94
(h)	Other non-current assets	125.99	132.81
	Total non-current assets (1)	5,223.75	5,003.25
	Current assets		
(a)	Inventories	2,020.96	1,936.54
(b)	Financial assets		
	(i) Trade receivables	1,859.44	2,007.16
	(ii) Cash and cash equivalents	49.77	99.54
	(iii) Bank balances other than Cash and cash equivalents	13.61	44.67
	(iv) Loans	1.53	0.93
	(v) Other financial assets	6.34	5.86
(c)	Other current assets	239.85	237.62
	Total current assets (2)	4,191.50	4,332.32
	Total - assets (1+2)	9,415.25	9,335.57
II	EQUITY AND LIABILITIES		
	Equity		
(a)	Equity share capital	107.96	107.85
(b)	Other equity	4,697.43	4,364.71
	Total equity attributable to equity holders of Holding Company	4,805.39	4,472.56
	Non-controlling interests	128.14	129.96
	Total equity (1)	4,933.53	4,602.52
	Non-current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	538.77	645.58
	(ii) Lease liabilities	54.26	62.19
(b)	Provisions	112.82	106.09
(c)	Deferred tax liability (net)	25.02	31.87
(d)	Other non-current liabilities	575.67	347.60
	Total non-current liabilities (2)	1,306.54	1,193.33
	Current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	1,610.58	2,047.50
	(ii) Trade payables		
	-total outstanding dues of micro enterprises and small enterprises	40.38	27.75
	-total outstanding dues of creditors other than micro enterprises and small enterprises	973.98	930.74
	(iii) Lease liabilities	8.15	8.46
	(iv) Other financial liabilities	281.27	337.61
(b)	Other current liabilities	120.75	101.12
(c)	Provisions	30.97	29.34
(d)	Income tax liabilities (net)	109.10	57.20
	Total current liabilities (3)	3,175.18	3,539.72
	Total - equity and liabilities (1+2+3)	9,415.25	9,335.57



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Consolidated Statement of Cash Flows

₹ in Crores

Particulars	For the six months ended September 30, 2025	For the six months ended September 30, 2024
	Unaudited	Unaudited
Profit before tax	493.95	41.27
Cash flow from operating activities		
Adjustments for:		
Depreciation and amortisation	237.33	213.57
Loss on sale of property, plant and equipment (net)	4.41	1.41
Interest income	(4.83)	(3.24)
Interest expenses	88.66	99.11
Share based payment expense	5.41	5.56
Net gain on foreign exchange fluctuations (unrealised)	(19.26)	(4.38)
Allowance for expected credit loss and bad debts (net)	52.09	19.90
Operating profit before working capital changes	857.76	373.20
Movement In working capital:		
Increase in inventories	(86.02)	(257.97)
(Increase)/Decrease in trade receivables	124.74	(100.39)
Increase in financial and non-financial assets	(22.05)	(30.14)
Increase in trade payables	59.14	6.84
Increase in financial, non-financial liabilities and provisions	253.81	104.82
Cash generated from operations	1,187.38	96.36
Income tax paid	(94.25)	(39.05)
Net cash generated from operating activities (A)	1,093.13	57.31
Cash flow from investing activities		
Purchase of property, plant and equipment, including intangible assets, and movement in capital work in progress, capital advances and capital creditors	(488.91)	(262.02)
Proceeds from sale of property, plant and equipment	2.97	3.18
Movement in Bank balances other than Cash and cash equivalents	31.06	1.51
Investment in associate	(9.07)	-
Investment in others	(17.65)	-
Interest received	4.83	3.24
Net cash used in investing activities (B)	(476.77)	(254.09)
Cash flow from financing activities		
Proceeds from exercise of employee stock options	18.95	6.82
Repayment of long - term borrowings	(178.18)	(153.34)
Proceeds from long - term borrowings	43.76	22.62
Proceeds from short - term borrowings (net)	(412.26)	348.21
Payment of lease liabilities	(6.41)	(6.96)
Dividend paid	(43.14)	(21.56)
Interest paid	(90.68)	(97.13)
Net cash generated/(used) from financing activities (C)	(667.96)	98.66
Net increase/(decrease) in cash and cash equivalents (A+B+C)	(51.60)	(98.12)
Effect of exchange differences on cash and cash equivalents	1.83	2.40
Cash and cash equivalents at the beginning of the period	99.54	138.94
Cash and cash equivalents at the period end	49.77	43.22



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Notes:

- The above consolidated unaudited financial results of Laurus Labs Limited ("the Company") including its subsidiaries (Collectively known as "the Group"), and its associates and joint venture (as mentioned in note 3) has been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on October 23, 2025. The statutory auditors of the Company have carried out a limited review on consolidated financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and six months ended September 30, 2025.
- These consolidated financial results of the Group have been prepared in accordance with the Indian Accounting Standards ("IND AS") prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- The consolidated financial results include the results of the following entities:

Name of the Company	Country of Incorporation	Nature of relationship	% Holding
Sriam Labs Private Limited	India	Subsidiary	100%
Laurus Holdings Limited	UK	Subsidiary	100%
Laurus Generics Inc	USA	Step-down subsidiary	100%
Laurus Generics GmbH	Germany	Step-down subsidiary	100%
Laurus Synthesis Private Limited	India	Subsidiary	100%
Laurus Generics SA (Pty) Ltd	South Africa	Subsidiary	100%
Laurus Bio Private Limited (Refer note 4b)	India	Subsidiary	77.44%
Laurus Specialty Chemicals Private Limited (Refer note 4a)	India	Subsidiary	100%
ImmunoAdoptive Cell Therapy Private Limited	India	Associate	34.89%
Ethan Energy India Private Limited	India	Associate	26.00%
KRKA Pharma Private Limited (Refer note 4c)	India	Joint Venture	49.00%

- The Company incorporated wholly owned subsidiary, Laurus Specialty Chemicals Private Limited (LSCPL) in India on December 01, 2022. LSCPL has not commenced its operations.
 - During the quarter ended June 30, 2025, the company has invested ₹ 40 Crores into Laurus Bio Private Limited as per the definitive agreement with Laurus Labs Limited (Parent Company), Eight Roads Ventures and F-Prime Capital ("Investors").
 - Pursuant to the joint venture agreement entered into by the Company with KRKA Pharma Private Limited ("KRKA"), Capital contribution have been made into KRKA in terms of the aforesaid agreement during the quarter ended December 31, 2024 for 49% stake. The Company has accounted for the investment in KRKA as joint venture w.e.f. October 03, 2024.
- Pursuant to investment agreement entered into by the Company with Kurnool Renewables Private Limited (Kurnool Renewables), capital contributions have been made into Kurnool Renewables in terms of the aforesaid agreement during the quarter ended June 30, 2025. The Company has accounted for its investment in Kurnool Renewables as an associate w.e.f. May 12, 2025.
- The Group is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108 - "Operating Segments".
- The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement ("the Scheme") for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi ("NCLT") under section 230 and 232 of the Companies Act, 2013 ("the Act") and other applicable provisions of the Act and the rules made thereunder. The Company has filed a petition with NCLT on October 11, 2025. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the consolidated financial results of the Company for the quarter and six months ended September 30, 2025, quarter ended June 30, 2025, quarter and six months ended September 30, 2024 and year ended March 31, 2025 are presented without giving effect to the said merger.
- During the quarter ended June 30, 2025, the Company allotted 572,408 equity shares of ₹ 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme.
- The Board of Directors, at their meeting held on October 23, 2025 approved for the payment of interim dividend of ₹ 0.80/- per equity share of ₹ 2/- each.

Place: Hyderabad
Date: October 23, 2025

By order of the Board
For Laurus Labs Limited



Dr. Satyanarayana Chava
Whole Time Director & Chief Executive Officer



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, E info@lauruslabs.com
F +91 891 682 1103, W lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF LAURUS LABS LIMITED

1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **LAURUS LABS LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit after tax and total comprehensive income of its associates and joint venture for the quarter and six months ended September 30, 2025 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
 - a. Laurus Labs Limited, the Parent
 - b. Laurus Bio Private Limited, India, Subsidiary
 - c. Sriam Labs Private Limited, India, Wholly Owned Subsidiary
 - d. Laurus Synthesis Private Limited, India, Wholly Owned Subsidiary
 - e. Laurus Holdings Limited, United Kingdom, Wholly Owned Subsidiary
 - f. Laurus Generics Inc., United States of America, (Subsidiary of (e) above)
 - g. Laurus Generics GmbH, Germany, (Wholly Owned Subsidiary of (e) above)
 - h. Laurus Generics SA (Pty) Limited, South Africa, Wholly Owned Subsidiary
 - i. Laurus Specialty Chemicals Private Limited, India, Wholly Owned Subsidiary
 - j. ImmunoAdoptive Cell Therapy Private Limited, India, Associate
 - k. Ethan Energy India Private Limited, India, Associate
 - l. KRKA Pharma Private Limited, India, Joint Venture

24

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of five subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflect total assets of ₹ 248.02 crores as at September 30, 2025, total revenues of ₹ 76.57 crores and ₹ 150.25 crores for the quarter and six months ended September 30, 2025 respectively, total net loss after tax of ₹ 19.03 crores and ₹ 39.98 crores for the quarter and six months ended September 30, 2025 respectively and total comprehensive loss of ₹ 19.03 crores and ₹ 39.98 crores for the quarter and six months ended September 30, 2025 respectively and net cash flows of ₹ 18.39 crores for the six months ended September 30, 2025, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of these matters.

7. The consolidated unaudited financial results also includes the Group's share of profit after tax of ₹ 1.16 crores and ₹ 1.22 crores for the quarter and six months ended September 30, 2025 respectively and total comprehensive income of ₹ 1.16 crores and ₹ 1.22 crores for the quarter and six months ended September 30, 2025 respectively, as considered in the Statement, in respect of an associate and one joint venture, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

C Manish Muralidhar
Partner

Membership No. 213649
UDIN: 25213649BMOEPM1777

Place: Hyderabad
Date: October 23, 2025

LAURUS LABS LIMITED
(CIN: L24239AP2005PLC047518)

Regd. Office: Laurus Enclave, Plot Office 01, E. Bonangi Village, Parawada Mandal, Anakapalli District, Andhra Pradesh - 531021
Corp. Office: 2nd Floor, SDE Serene Chambers, Road No.7, Banjara Hills, Hyderabad 500034, Telangana, India.
Tel: +91 040 3980 4333 ; Fax : +91 040 3980 4320 ; E-mail: secretarial@lauruslabs.com; Website: www.lauruslabs.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 2025

₹ in Crores

Sl. No.	Particulars	Quarter ended			Six months ended		Year ended
		30-Sep-25 (Unaudited)	30-Jun-25 (Unaudited)	30-Sep-24 (Unaudited)	30-Sep-25 (Unaudited)	30-Sep-24 (Unaudited)	31-Mar-25 (Audited)
1	Income						
	(a) Revenue from operations	1,566.60	1,432.75	1,184.85	2,999.35	2,301.78	5,216.98
	(b) Other income	28.45	21.52	11.89	49.97	21.19	100.47
	Total income	1,595.05	1,454.27	1,196.74	3,049.32	2,322.97	5,317.45
2	Expenses						
	(a) Cost of materials consumed	644.40	572.89	581.24	1,217.29	1,138.19	2,371.38
	(b) Purchase of traded goods	30.70	38.50	25.59	69.20	48.26	105.36
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(25.58)	(1.18)	(45.99)	(26.76)	(105.65)	(13.55)
	(d) Employee benefits expense	182.31	179.90	148.94	362.21	298.17	608.64
	(e) Other expenses	345.11	315.26	293.24	660.37	579.59	1,200.82
	(f) Depreciation and amortisation expense	95.59	93.57	90.94	189.16	181.94	358.79
	(g) Finance costs	33.68	43.89	44.69	77.57	85.58	182.20
	Total expenses	1,306.21	1,242.83	1,138.65	2,549.04	2,226.08	4,813.64
3	Profit before tax (1-2)	288.84	211.44	58.09	500.28	96.89	503.81
4	Tax expense						
	(a) Current tax	87.93	59.66	21.97	147.59	39.23	153.84
	(b) Deferred tax	(14.76)	(6.16)	(6.32)	(20.92)	(13.56)	(30.42)
	Total Tax expense	73.17	53.50	15.65	126.67	25.67	123.42
5	Net Profit after tax (3-4)	215.67	157.94	42.44	373.61	71.22	380.39
6	Other comprehensive income						
	Items that will not be reclassified subsequently to profit or loss:						
	(i) Remeasurement gains/(losses) on defined benefit plans	(0.26)	(0.25)	0.38	(0.51)	0.76	(1.02)
	(ii) Income tax relating to items that will not be reclassified to profit or loss in subsequent periods	0.07	0.06	(0.09)	0.13	(0.19)	0.26
	Total other comprehensive income/(loss), net of tax	(0.19)	(0.19)	0.29	(0.38)	0.57	(0.76)
7	Total comprehensive income (5+6)	215.48	157.75	42.73	373.23	71.79	379.63
8	Paid-up equity share capital (face value ₹ 2/- each)	107.96	107.96	107.83	107.96	107.83	107.85
9	Other equity						4,456.10
10	Earnings per equity share (face value ₹ 2/- each)						
	- Basic (₹)	3.99	2.93	0.79	6.92	1.32	7.06
	- Diluted (₹)	3.99	2.93	0.79	6.92	1.32	7.05
		(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)

See accompanying notes to the financial results



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, E info@lauruslabs.com
F +91 891 682 1103, W lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Standalone Balance Sheet		₹ in Crores	
Sl. No.	Particulars	As at September 30, 2025	As at March 31, 2025
		Unaudited	Audited
I	ASSETS		
	Non-current assets		
(a)	Property, plant and equipment	2,832.28	2,762.97
(b)	Right-of-use assets	97.92	106.90
(c)	Capital work-in-progress	438.18	336.24
(d)	Other Intangible assets	16.04	17.63
(e)	Financial assets		
	(i) Investments	806.94	740.22
	(ii) Other financial assets	40.37	44.01
	(iii) Loans	466.00	466.50
(f)	Other non-current assets	97.61	105.50
	Total non-current assets (1)	4,795.34	4,579.97
	Current assets		
(a)	Inventories	1,813.06	1,738.88
(b)	Financial assets		
	(i) Trade receivables	1,906.47	2,035.07
	(ii) Cash and cash equivalents	0.31	50.36
	(iii) Bank balances other than Cash and cash equivalents	0.27	0.28
	(iv) Loans	5.09	6.69
	(v) Other financial assets	12.10	12.93
(c)	Other current assets	159.75	162.57
	Total current assets (2)	3,897.05	4,006.78
	Total - assets (1+2)	8,692.39	8,586.75
II	EQUITY AND LIABILITIES		
	Equity		
(a)	Equity share capital	107.96	107.85
(b)	Other equity	4,810.44	4,456.10
	Total equity (1)	4,918.40	4,563.95
	Liabilities		
	Non-current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	344.54	414.25
	(ii) Lease liabilities	39.05	46.90
(b)	Provisions	102.36	96.72
(c)	Deferred tax liability (net)	14.59	35.63
(d)	Other non-current liabilities	469.00	267.26
	Total non-current liabilities (2)	969.54	860.76
	Current liabilities		
(a)	Financial liabilities		
	(i) Borrowings	1,429.47	1,910.39
	(ii) Trade payables		
	-total outstanding dues of micro enterprises and small enterprises	33.55	24.46
	-total outstanding dues of creditors other than micro enterprises and small enterprises	940.91	904.24
	(iii) Lease liabilities	7.90	8.22
	(iv) Other financial liabilities	213.80	194.01
(b)	Other current liabilities	42.30	39.63
(c)	Provisions	29.43	27.63
(d)	Income tax liabilities (net)	107.09	53.46
	Total current liabilities (3)	2,804.45	3,162.04
	Total - equity and liabilities (1+2+3)	8,692.39	8,586.75



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC04751B,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Standalone Statement of Cash Flows

₹ in Crores

Particulars	For the six months ended September 30, 2025	For the six months ended September 30, 2024
	Unaudited	Unaudited
Profit before tax	500.28	96.89
Cash flow from operating activities		
Adjustments for :		
Depreciation and amortisation	189.16	181.94
Loss on sale of property, plant and equipment (net)	1.49	0.93
Finance income	(24.97)	(14.56)
Interest expense	75.45	83.24
Share based payment expense	5.41	5.56
Net gain on foreign exchange fluctuations (unrealised)	(10.92)	(3.63)
Allowance for expected credit loss and bad debts (net)	51.39	19.87
Operating profit before working capital changes	787.29	370.24
Movement in working capital:		
Increase in inventories	(74.19)	(226.56)
(Increase)/Decrease in trade receivables	103.13	(147.29)
Increase in financial and non-financial assets	(2.56)	(14.54)
Increase in trade payables	36.79	17.32
Increase in financial, non-financial liabilities and provisions	211.32	90.27
Cash generated from operations	1,061.78	89.44
Income tax paid	(93.96)	(40.47)
Net cash generated from operating activities (A)	967.82	48.97
Cash flow from investing activities		
Purchase of property, plant and equipment, including intangible assets, and movement in capital work in progress, capital advances and capital creditors	(319.48)	(140.00)
Proceeds from sale of property, plant and equipment	2.47	2.73
Movement in Bank balances other than Cash and cash equivalents	0.01	-
Investment in associate	(9.07)	-
Investment in others	(17.65)	-
Investment in subsidiaries	(40.00)	-
Loan given to subsidiaries	(129.50)	(144.00)
Loan repaid by subsidiaries	132.00	53.00
Interest received	24.97	14.55
Net cash used in investing activities (B)	(356.25)	(213.72)
Cash flow from financing activities		
Proceeds from exercise of employee stock options	18.95	6.86
Repayment of long - term borrowings	(139.00)	(121.98)
Proceeds from long - term borrowings	43.76	22.62
Proceeds from Short - term borrowings (net)	(458.36)	335.46
Payment of lease liabilities	(5.79)	(6.11)
Dividend paid	(43.14)	(21.56)
Interest paid	(78.04)	(82.26)
Net cash generated/(used) from financing activities (C)	(661.62)	133.03
Net increase in cash and cash equivalents (A+B+C)	(50.05)	(31.72)
Cash and cash equivalents at the beginning of the period	50.36	42.63
Cash and cash equivalents at the period end	0.31	10.91



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, E info@lauruslabs.com
F +91 891 682 1103, W lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.


T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

Notes:

- 1 The above standalone unaudited financial results of Laurus Labs Limited ("the Company") has been reviewed by the Audit Committee has been approved by the Board of Directors at its meeting held on October 23, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results and have issued an unmodified conclusion in respect of the limited review for the quarter and six months ended September 30, 2025.
- 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards ('IND AS') prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI").
- 3 The Company is engaged in the manufacture and sale of "Pharmaceuticals" which constitutes a single reportable business segment as per Ind AS 108 - 'Operating Segments'.
- 4 The Board of Directors of the Company, in its meeting held on August 21, 2025, approved the proposed Composite Scheme of Arrangement ("the Scheme") for the demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Srium Labs Private Limited and amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with the Company, subject to the necessary approval from National Company Law Tribunal, Amaravathi ("NCLT") under section 230 and 232 of the Companies Act, 2013 ("the Act") and other applicable provisions of the Act and the rules made thereunder. The Company has filed a petition with NCLT on October 11, 2025. Upon approval of the Scheme, Laurus Synthesis Private Limited shall stand dissolved without winding up with the Appointed Date of April 01, 2026 or such other date as the NCLT may approve. Pending such approval, the standalone financial results of the Company for the quarter and six months ended September 30, 2025, quarter ended June 30, 2025, quarter and six months ended September 30, 2024 and year ended March 31, 2025 are presented without giving effect to the said merger.
- 5 During the quarter ended June 30, 2025, the Company allotted 572,408 equity shares of ₹ 2/- each, consequent to the exercise of the stock options by the employees of the Company under the Employee Stock Option Scheme.
- 6 The Board of Directors, at their meeting held on October 23, 2025 approved for the payment of interim dividend of ₹ 0.80/- per equity share of ₹ 2/- each.

Place: Hyderabad
Date : October 23, 2025

By order of the Board
For Laurus Labs Limited



Dr. Satyanarayana Chava
Dr. Satyanarayana Chava
Whole Time Director & Chief Executive Officer



Registered Office

Laurus Enclave, Plot Office 01, E. Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **E** info@lauruslabs.com
F +91 891 682 1103, **W** lauruslabs.com

CIN : L24239AP2005PLC047518,

Corporate Office

2nd Floor, SDE Serene Chambers, Road No. 7,
Banjara Hills, Hyderabad - 500034, Telangana, India.

T +91 40 6659 4333, 3980 4333, 2342 0500 / 501,
F +91 40 6659 4320 / 3980 4320

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF LAURUS LABS LIMITED

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of **LAURUS LABS LIMITED** ("the Company"), for the quarter and six months ended September 30, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

C Manish Muralidhar
Partner

Membership No. 213649
UDIN: 25213649BMOEPN4460

Place: Hyderabad
Date: October 23, 2025